Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis.

TL;DR

Systematic review and meta-analysis found no statistically significant increase in depression, anxiety, or suicidal ideation/attempt with semaglutide versus comparators, though pooled risk ratios hovered near unity with wide confidence intervals suggesting possible small increases cannot be excluded.

Key findings

• Pooled risk ratio for depression was 1.25 (95% CI: 0.95-1.65), not statistically significant, with very high heterogeneity (I² = 98%).
• Anxiety and suicidal ideation/attempt also showed non-significant associations (RR 1.22 and 1.20 respectively) with substantial heterogeneity.
• Evidence certainty limited by high heterogeneity across studies, risk of bias, and heterogeneous data sources including pharmacovigilance spontaneous-reporting systems.
• Findings represent absence of detected increased risk in available evidence rather than definitive exclusion of psychiatric effects.

Why this matters at the bedside

Provides reassurance on neuropsychiatric safety of semaglutide in clinical practice for T2DM and obesity, though prescribers should remain alert to individual cases and counsel patients on monitoring mood symptoms given uncertainty in the evidence base.